Speaker

Sai Vemula

Associate Director, Translational Medicine, Immuno Oncology, Bristol Myers Squibb

Sai Vemula, Associate Director, Translational Medicine, Immuno Oncology at Bristol Myers Squibb, spoke at 8th RAS-Targeted Drug Development Summit (Boston, United States of America, 8–10 Sept 2026) in the session “Panel Discussion: Setting the Boundaries of What’s Clinically Achievable in RAS Therapy Defining the Realistic Therapeutic Window for Next-Generation Strategies”.

Conferences: 1
Keynotes: 0
Upcoming: 0

Pharmacy & Pharmaceutical Sciences

Past appearances

8th RAS-Targeted Drug Development Summit
8–10 Sept 2026Boston, United States of America
- PanelPanel Discussion: Setting the Boundaries of What’s Clinically Achievable in RAS Therapy Defining the Realistic Therapeutic Window for Next-Generation StrategiesWith Federico Innocenti, Luke Pase

More speakers at 8th RAS-Targeted Drug Development Summit

Nagi Ayad
Professor, Georgetown University
Stephanie Braun
Executive Director & Head of Enzalutamide, Medical Affairs (US), Astellas Pharma
Silvia Coma
Senior Director, Translational & Preclinical Research, Verastem, inc
Peter DeMuth
Chief Scientific Officer, Elicio Therapeutics
Matthew Farren
Senior Research, Pharmacology Investigator, Incyte Corporation
George Fromm
Chief Scientific Officer, KAYAK

See all 30 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Sai Vemula, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].